|
Wall Street Analysts Have $21 Price Target on NxStage Medical, Inc. (NASDAQ:NXTM) - Markets Daily |
 |
|
There are 4 research firms in total that have issued ratings on NxStage Medical, Inc. (NASDAQ:NXTM) within the past year. The consensus, or mean target price of the Wall Street analysts covering the firm is $21.
Analysts are predicting that NxStage Medical, Inc. (NASDAQ:NXTM) will report $-0.1 earnings per share when they next issue their quarterly earnings release on or around 2015-08-06. The consensus mean estimate is the calculated mean of all brokerage sell-side analysts that issue earnings estimates for the company. In the most recent quarter the company reported earnings of $0 that ended on 2015-03-31. NxStage Medical, Inc. (NASDAQ:NXTM) has a 2 consensus analyst rating on the stock based on an arithmetical average of the 4 ratings given by the brokerage analysts covering the company. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell. The highest estimate of the 4 covering analysts sees the stock climbing to $24 within the next year while the lowest estimate places the 12-month target price at $15. Looking ahead to full year estimates, analysts have placed the consensus earnings per share estimate for the current year at $-0.35. The most bullish analyst sees the company reporting earnings per share of $-0.31 while the most bearish analyst is predicting a current year EPS number of $-0.42. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
|